UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study.
The U.S. Centers for Disease Control and Prevention recently awarded a $10 million grant to a team led by Rhoel Dinglasan to test why are some countries in the grip of COVID-19 while others appear less affected.
Officials in India are racing to contain a virus outbreak that has claimed the life of a 12-year-old boy and is deadlier than COVID-19 — the Nipah virus.
One area where COVID-19 has had a substantial impact is the development and manufacturing of medicines, medical devices, and pharmaceutical products. The CDMO industry is showing enormous growth and is projected to become a $315 billion industry by 2026. However, the demand for products skyrocketed so quickly that supply has not been able to keep pace. According to Dr. Ian White, president and CSO of Neobiosis, a UF Innovate | Sid Martin Biotech resident company that focuses on the science of regenerative medicine, demand has caused a two-year backlog of desperately needed cellular and acellular products for use in research and clinical trials directed at treating the COVID-19 virus and its complications (AKA Post-COVID Syndrome).
The breast milk of lactating mothers vaccinated against COVID-19 contains a significant supply of antibodies that may help protect nursing infants from the illness, according to new research from the University of Florida.
UF Innovate | Sid Martin Biotech alum DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world.
A multidisciplinary team of researchers at the University of Florida is making progress in their search for targets that could be used for developing treatments for infections with COVID-19. The team posted a paper to bioRxiv reporting the identification of 53 novel genes and pathways that could become druggable targets for antiviral therapies for COVID-19 plus a broad array of coronavirus types.
The University of Florida is reflecting back on the milestones made in the last year through the COVID-19 pandemic. From the initial lockdown in March 2020 to the rollout of vaccines in December, reflecting back on the year of change helps us see just how far we’ve come.
People who have recovered from a bout of severe COVID-19 may still have a reason for concern about their health. A new University of Florida study has found that patients who had a severe case of the disease were more than twice as likely as patients who had mild or moderate COVID-19 to need hospitalization again for health problems caused by COVID-19 complications.
A new University of Florida study finds that patients with COVID-19 who displayed symptoms of disorientation and confusion were three times more likely to go on to develop severe COVID-19 than patients with the virus who did not experience neurological symptoms.
